 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Zonagen, Inc.
 |
Zonagen, Inc. |
 |
 |
 |
PROFILE |
 |
Zonagen zeroes in on your private zones. Its lead drug candidate, VASOMAX, is a pill for male erectile dysfunction. The company is also developing Vasofem, a treatment for female sexual dysfunction. Other products in the pipeline include contraceptives, vaccines for prostate cancer, and an enhanced topical treatment for genital herpes. Drug firm Schering-Plough has licensed the marketing rights to VASOMAX, which was approved in Brazil and in Mexico (under the name Z-Max), but FDA approval in the US has been delayed. Because of these delays, Zonagen has cut its R&D and its staff to reduce costs.
COMPETITION |
 |
ICOS Corporation (ICOS)
Pfizer Inc (PFE)
VIVUS, Inc. (VVUS)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 2.40
1-Yr. Sales Growth: 1,100.0%
Employees: 11
Revenue per employee: $218,181.82
KEY PEOPLE |
 |
Joseph S. Podolski
CEO
Louis Ploth
CFO
CONTACT INFO |
 |
2408 Timberloch Place, Ste. B-4
The Woodlands, TX 77380
US
Phone: 281-367-5892
Fax: 281-363-8796
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |